コンテンツへスキップ
Merck

Rheumatic manifestations of cocaine use.

Current opinion in rheumatology (2012-12-01)
Jonathan Graf
要旨

Cocaine use is associated with several rheumatic syndromes. This review summarizes these clinical manifestations and highlights recent developments linked to levamisole-adulterated cocaine. Cocaine use has been linked to several distinctive syndromes that can be difficult to distinguish from idiopathic rheumatic diseases. These disorders can range in severity from purely cosmetic damage to organ and/or life-threatening disease that includes sinonasal destruction and vasculitis. Many of these illnesses are associated with antineutrophil cytoplasmic antibodies (cytoplasmic, perinuclear and atypical perinuclear patterns). With the recent introduction of levamisole as a cocaine adulterant, a newly reported syndrome has emerged that is associated with neutropenia, retiform purpura with cutaneous necrosis and autoantibodies consisting of high-titre perinuclear antineutrophil cytoplasmic antibodies (p-ANCAs) with specificities for 'atypical' antigens. Cocaine use is associated with clinical syndromes that closely mimic other primary rheumatic diseases. Given the high prevalence of cocaine use and its adulteration with levamisole, clinicians should be familiar with these rheumatic manifestations in order to avoid misdiagnosis and unnecessary treatment with potentially toxic therapies.

材料
製品番号
ブランド
製品内容

Sigma-Aldrich
(−)-テトラミゾール 塩酸塩, ≥99% (GC)
Supelco
レバミゾール 塩酸塩, VETRANAL®, analytical standard
Supelco
(−)-Levamisole hydrochloride solution, 1.0 mg/mL in methanol (as free base), ampule of 1 mL, certified reference material, Cerilliant®
(−)-テトラミゾール 塩酸塩, European Pharmacopoeia (EP) Reference Standard
システム適合性用レバミゾール塩酸塩, European Pharmacopoeia (EP) Reference Standard